C1-esterase inhibitor in early septicemia.
In bacteremic pigs, both administered human C1INH and endogenous C1INH lost inhibitory activity. In septic pigs which received human C1INH a difference between immunologically determined concentration and inhibitory activity of C1INH became apparent. In animals which survived at least 24 hrs the C1INH activity showed an acute phase response. In a model of E. coli bacteremia in weaned pigs administration of human C1INH showed protective effects on lung capillary permeability as well as less leucocytosis.
D000818:Animals; D003174:Complement C1 Inactivator Proteins / Q000627:therapeutic use*; D004927:Escherichia coli Infections / Q000628:therapy; D007958:Leukocyte Count / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D011288:Prekallikrein / Q000097:blood; D011654:Pulmonary Edema / Q000517:prevention & control; D018805:Sepsis / Q000097:blood / Q000628:therapy*; D013552:Swine; D000511:alpha-Macroglobulins / Q000378:metabolism
D003174:Complement C1 Inactivator Proteins; D000511:alpha-Macroglobulins; D011288:Prekallikrein